Adam Feuerstein and Jason Mast

BioTech

Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals

Adam Feuerstein and Jason Mast November 5, 2024

BioTech

Pfizer pulls sickle cell treatment Oxbryta off global markets

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks

Adam Feuerstein and Jason Mast September 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Adam Feuerstein and Jason Mast

Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment

Pfizer pulls sickle cell treatment Oxbryta off global markets

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe